SCI时时刷

search
+
BrECADD raises the bar in classical Hodgkin lymphoma
The eBEACOPP regimen, consisting of bleomycin, vincristine, procarbazine and prednisone plus escalated doses of etoposide,...
Tisotumab vedotin effective in recurrent cervical cancer
Patients with recurrent advanced-stage and/or metastatic cervical cancer typically have a poor prognosis with limited trea...
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma
BCMA-directed chimeric antigen receptor T cell therapies and bispecific T cell engagers are moving to earlier lines of the...
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
A better understanding of the roles of the adaptive and innate immune systems in the oncogenesis of cancers including mult...
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer
Small-cell lung cancer (SCLC) has traditionally been considered a recalcitrant cancer with a dismal prognosis, with only m...
Is NETTER-2 a practice-changing trial?
The NETTER-2 trial provides the first phase III evidence that 177Lu-dotatate is active as first-line therapy in patients w...
Targeting chromosomal instability in patients with cancer
Targeting chromosomal instability in patients with cancer
Chromosomal instability (CIN) is a hallmark of cancer and a driver of metastatic dissemination, therapeutic resistance, an...
Asciminib is safe and effective in patients with newly diagnosed CML
Four BCR–ABL1 tyrosine-kinase inhibitors (TKIs) are approved for patients with newly diagnosed chronic myeloid leukaemia (...
Vimseltinib improves outcomes in tenosynovial giant cell tumour
Tenosynovial giant cell tumour (TGCT) is a locally aggressive neoplasm of the tendons and cannot always be managed surgica...
NICHE-2 validates the efficacy of neoadjuvant ICIs in dMMR colon cancer
Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced-stage DNA mismatch repair-deficient (dMM...
Promising outcomes with liso-cel in patients with R/R follicular lymphoma
Promising outcomes with liso-cel in patients with R/R follicular lymphoma
Patients with follicular lymphoma (FL) generally have favourable outcomes after receiving first-line immunochemotherapy; h...
Addition of sintilimab to standard therapy improves event-free survival
Patients with locoregionally advanced nasopharyngeal carcinoma (NPC) typically receive induction chemotherapy followed by ...
Osimertinib efficacious as maintenance therapy in patients with stage III NSCLC
Patients diagnosed with unresectable stage III non-small-cell lung cancer (NSCLC) typically receive concurrent chemoradiot...
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM
Quadruplet regimens comprising an anti-CD38 antibody, proteasome inhibitor, immunomodulatory agent and a glucocorticoid ha...
Neoadjuvant ipilimumab–nivolumab superior to adjuvant nivolumab
Data from phase II trials indicate that patients with resectable melanoma are likely to derive benefit from neoadjuvant im...
Towards equitable AI in oncology
Towards equitable AI in oncology
Artificial intelligence (AI) stands at the threshold of revolutionizing clinical oncology, with considerable potential to ...
Exploiting bacteria for cancer immunotherapy
Exploiting bacteria for cancer immunotherapy
Immunotherapy has revolutionized the treatment of cancer but continues to be constrained by limited response rates, acquir...
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Research into bispecific antibodies, which are designed to simultaneously bind two antigens or epitopes, has advanced enor...
RADICALS-HD sheds light on the role of ADT addition to post-operative radiotherapy
The addition of short-course androgen-deprivation therapy (ADT) to upfront radiotherapy is the standard-of-care approach f...
Ponatinib superior to imatinib in Ph+ ALL
Ponatinib superior to imatinib in Ph+ ALL
BCR–ABL1 tyrosine kinase inhibitors, in combination with chemotherapy and/or steroids, are the standard-of-care therapy fo...
Adding ibrutinib to frontline therapy improves outcomes in transplant-eligible patients with MCL
For eligible patients with mantle cell lymphoma (MCL), consolidative autologous haematopoietic stem cell transplantation (...
Gaining ground in personalized breast cancer therapy: lesson learned from PHERGain
De-escalation of treatment for HER2+ breast cancer is a priority, given the increase in cure rates owing in part to improv...
Current understanding and management of CAR T cell-associated toxicities
Current understanding and management of CAR T cell-associated toxicities
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of several haematological malignancies and...
Predicting tumour origin with cytology-based deep learning: hype or hope?
The majority of patients with cancers of unknown primary have unfavourable outcomes when they receive empirical chemothera...
Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination
Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination
Cervical cancer is the first cancer deemed amenable to elimination through prevention, and thus lessons from the epidemiol...
Cancer mRNA vaccines: clinical advances and future opportunities
Cancer mRNA vaccines: clinical advances and future opportunities
mRNA vaccines have been revolutionary in terms of their rapid development and prevention of SARS-CoV-2 infections during t...
CAR T cells in multiple myeloma: lessons learned
The question of whether chimeric antigen receptor (CAR) T cell therapies should be used in earlier lines (after 1–2 ...
NIR-II light in clinical oncology: opportunities and challenges
NIR-II light in clinical oncology: opportunities and challenges
Novel strategies utilizing light in the second near-infrared region (NIR-II; 900–1,880 nm wavelengths) offer t...
Laparoscopic hemihepatectomy is safe and effective
Liver resection is an essential component of the management of patients with various primary or metastatic liver cancers, ...
Adjuvant pembrolizumab improves overall survival in patients with RCC
Adjuvant therapy with the anti-PD-1 antibody pembrolizumab has been shown to significantly improve disease-free survival (...
阅读更多
format_indent_increase